NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2014
Summary
Global Markets Direct’s, ‘NAL Pharmaceuticals Ltd. - Product Pipeline Review - 2014’, provides an overview of the NAL Pharmaceuticals Ltd.’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of NAL Pharmaceuticals Ltd.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of NAL Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of NAL Pharmaceuticals Ltd.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the NAL Pharmaceuticals Ltd.’s pipeline products
Reasons to buy
- Evaluate NAL Pharmaceuticals Ltd.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of NAL Pharmaceuticals Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the NAL Pharmaceuticals Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of NAL Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of NAL Pharmaceuticals Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of NAL Pharmaceuticals Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
NAL Pharmaceuticals Ltd. Snapshot 6
NAL Pharmaceuticals Ltd. Overview 6
Key Information 6
Key Facts 6
NAL Pharmaceuticals Ltd. - Research and Development Overview 7
Key Therapeutic Areas 7
NAL Pharmaceuticals Ltd. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
NAL Pharmaceuticals Ltd. - Pipeline Products Glance 12
NAL Pharmaceuticals Ltd. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
NAL Pharmaceuticals Ltd. - Unknown Stage Pipeline Products 13
Unknown Products/Combination Treatment Modalities 13
NAL Pharmaceuticals Ltd. - Drug Profiles 15
pegfilgrastim 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
diclofenac sodium 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
donepezil hydrochloride 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
donepezil hydrochloride Patch 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
formoterol fumarate patch 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
galantamine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
indomethacin 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
ketoprofen 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
levocetirizine dihydrochloride 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
montelukast sodium 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NAL-3216 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
NAL-3221 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
NAL-3223 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
nicotine bitartrate 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
rizatriptan benzoate 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sildenafil citrate 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
sufentanil 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
tadalafil 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
tulobuterol 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NAL Pharmaceuticals Ltd. - Pipeline Analysis 34
NAL Pharmaceuticals Ltd. - Pipeline Products by Target 34
NAL Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 35
NAL Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 36
NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 37
NAL Pharmaceuticals Ltd. - Dormant Projects 38
NAL Pharmaceuticals Ltd. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41
List Of Tables
List of Tables
NAL Pharmaceuticals Ltd., Key Information 6
NAL Pharmaceuticals Ltd., Key Facts 6
NAL Pharmaceuticals Ltd. - Pipeline by Indication, 2014 9
NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014 10
NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014 11
NAL Pharmaceuticals Ltd. - Preclinical, 2014 12
NAL Pharmaceuticals Ltd. - Unknown, 2014 13
NAL Pharmaceuticals Ltd. - Pipeline by Target, 2014 34
NAL Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2014 35
NAL Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2014 36
NAL Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014 37
NAL Pharmaceuticals Ltd. - Dormant Developmental Projects,2014 38
List Of Figures
List of Figures
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2014 8
NAL Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014 10
NAL Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014 11
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Target, 2014 34
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Route of Administration, 2014 35
NAL Pharmaceuticals Ltd. - Pipeline by Top 10 Molecule Type, 2014 36
NAL Pharmaceuticals Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014 37
